[
  {
    "id": 281,
    "question": "Stroke patient and he has fever, Cardiac consultation showed pan systolic murmur; what is the treatment:",
    "option_a": "antiplatelets",
    "option_b": "Antibiotics",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case represents an embolic stroke secondary to infective endocarditis. The combination of fever and a pansystolic murmur raises suspicion for an infectious process on the heart valves, which can lead to septic emboli causing stroke.\n\n**Pathophysiology**\n\nIn infective endocarditis, bacterial colonization of the heart valves produces vegetations that can break off and embolize to cerebral vessels. The inflammatory response and infection contribute to the clinical picture, and the vegetations are typically friable, leading to systemic embolization.\n\n**Clinical Correlation**\n\nPatients with infective endocarditis may present with stroke symptoms accompanied by systemic signs of infection (fever, malaise) and cardiac findings (e.g., a pansystolic murmur from regurgitant flow). The combination of these findings should prompt evaluation for endocarditis.\n\n**Diagnostic Approach**\n\nThe diagnostic approach includes obtaining multiple blood cultures and performing echocardiography (with transesophageal echocardiography being more sensitive) to identify vegetations. Differential diagnoses include non-infectious embolic strokes (e.g., cardioembolism from atrial fibrillation), which are less likely to present with fever.\n\n**Management Principles**\n\nThe current guidelines (AHA/ACC) recommend prompt initiation of empiric, then culture-guided, intravenous antibiotic therapy as the first line treatment in infective endocarditis. In cases complicated by large vegetations, heart failure, or uncontrolled infection, surgical intervention may be necessary. In pregnant and lactating patients, antibiotic selection should favor agents with proven safety profiles (e.g., penicillins and cephalosporins) while avoiding those known to carry teratogenic risks.\n\n**Option Analysis**\n\nOption A (antiplatelets) is insufficient because it does not address the underlying infection, whereas Option B (antibiotics) directly treats the bacterial cause of infective endocarditis, making it the correct choice. Unspecified options C and D add no therapeutic benefit in this scenario.\n\n**Clinical Pearls**\n\n1) In any stroke patient with fever and a new murmur, always consider infective endocarditis. 2) Early detection and targeted antibiotic therapy are critical to reduce the risk of catastrophic embolic events.\n\n**Current Evidence**\n\nRecent research emphasizes early multimodal imaging and the use of advanced echocardiographic techniques to detect vegetations. Updated guidelines stress the importance of individualized antibiotic regimens based on microbial susceptibility, along with a multidisciplinary approach in managing complicated cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 282,
    "question": "60 years old came to ER with left side weakness and left decrease propioception and right tongue weakness; what is the artery involved?",
    "option_a": "Rigth Vert",
    "option_b": "Left Vert",
    "option_c": "Basilar",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis is a classic example of a crossed or alternating brainstem syndrome, where a lesion in the medulla produces ipsilateral cranial nerve deficits and contralateral motor and sensory deficits.\n\n**Pathophysiology**\n\nMedial medullary syndrome (Dejerine syndrome) results from an infarct in the medial portion of the medulla. It affects the corticospinal tract and medial lemniscus, leading to contralateral weakness and loss of proprioception, as well as the hypoglossal nucleus or nerve, which causes tongue weakness on the same side as the lesion.\n\n**Clinical Correlation**\n\nThe patient\u2019s presentation of left-sided body weakness and loss of proprioception with right-sided tongue weakness indicates a lesion in the right medial medulla. The tongue weakness (ipsilateral to the lesion) and contralateral limb deficits are hallmark features of medial medullary syndrome.\n\n**Diagnostic Approach**\n\nMagnetic resonance imaging (MRI) of the brainstem is the investigation of choice. Vascular imaging with CT angiography or MR angiography helps in identifying the occluded vessel. Differential diagnoses include lateral medullary syndrome (Wallenberg syndrome) and pontine infarcts, but these present with different cranial nerve involvements.\n\n**Management Principles**\n\nThe standard management in acute stroke settings includes assessment for thrombolytic therapy eligibility. Secondary prevention strategies, such as antiplatelet agents and risk factor management (e.g., blood pressure control), are also essential. In pregnancy and lactation, thrombolytic agents and low-dose aspirin may be employed after careful risk assessment, as they are relatively safe when used appropriately.\n\n**Option Analysis**\n\nOption A (Right Vert) is correct because the right vertebral artery supplies the medial medulla where the lesion resides. Option B (Left Vert) would imply a lesion on the left medulla, which would lead to ipsilateral tongue weakness on the left, and Option C (Basilar) is more likely to affect different brainstem territories.\n\n**Clinical Pearls**\n\n1) Alternating (crossed) neurological deficits are highly indicative of a brainstem stroke. 2) Medial medullary syndrome classically presents with contralateral hemiparesis and loss of proprioception alongside ipsilateral hypoglossal nerve dysfunction.\n\n**Current Evidence**\n\nRecent advances in neuroimaging have enhanced the localization of brainstem infarcts, and updated stroke management guidelines continue to prioritize rapid intervention with thrombolytic therapy where applicable.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 283,
    "question": "Stroke patient has livedo reticularis what is the Dx?",
    "option_a": "Sneddon disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSneddon disease (or syndrome) is defined by the association of livedo reticularis\u2014a characteristic net-like pattern on the skin\u2014with cerebrovascular events such as strokes.\n\n**Pathophysiology**\n\nThe underlying mechanism is believed to be a non-inflammatory thrombotic arteriopathy affecting medium-sized arteries, which may be related to the presence of antiphospholipid antibodies. This leads to occlusion of vessels in both the skin and the brain, resulting in the observed manifestations.\n\n**Clinical Correlation**\n\nPatients with Sneddon syndrome typically present with recurrent strokes or transient ischemic attacks in conjunction with the skin finding of livedo reticularis. Cognitive impairment and other systemic manifestations may also occur.\n\n**Diagnostic Approach**\n\nDiagnosis involves clinical evaluation, skin examination, and supportive investigations such as antiphospholipid antibody testing and vascular imaging. Differential diagnoses include antiphospholipid syndrome, vasculitis, and systemic lupus erythematosus, which can present with overlapping features.\n\n**Management Principles**\n\nTreatment centers on preventing further thromboembolic events, typically using antiplatelet therapy or anticoagulation depending on the presence of antiphospholipid antibodies. In pregnant women, low molecular weight heparin in combination with low-dose aspirin is often recommended to reduce the risk of thrombosis while maintaining safety for both mother and fetus.\n\n**Option Analysis**\n\nOption A (Sneddon disease) is the correct diagnosis given the presentation of livedo reticularis and stroke. Other options, if provided, do not typically manifest with this distinctive combination of clinical findings.\n\n**Clinical Pearls**\n\n1) The presence of livedo reticularis in a stroke patient should prompt evaluation for Sneddon syndrome. 2) Consider testing for antiphospholipid antibodies when Sneddon syndrome is suspected, as it guides therapeutic decisions.\n\n**Current Evidence**\n\nRecent studies have further elucidated the role of immune-mediated thrombotic mechanisms in Sneddon syndrome, and evolving guidelines emphasize a tailored approach to anticoagulation versus antiplatelet therapy based on individual risk factors and antibody status.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 284,
    "question": "pt with stroke and had fibromuscular dysplasia, what next:",
    "option_a": "Renal Angio",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory arterial disease that commonly affects medium-sized arteries, most notably the renal and carotid arteries.\n\n**Pathophysiology**\n\nFMD results from abnormal cellular proliferation and architectural distortion of the arterial wall, often producing a characteristic 'string-of-beads' appearance on angiography. When it involves the carotid or vertebral arteries, it can predispose to cerebrovascular events, whereas renal artery involvement may lead to renovascular hypertension.\n\n**Clinical Correlation**\n\nIn a stroke patient found to have FMD, it is essential to evaluate for multisystem arterial involvement. The detection of FMD in the cerebrovascular circulation raises the possibility of concurrent renal artery disease, which has important implications for blood pressure management and overall vascular risk.\n\n**Diagnostic Approach**\n\nImaging studies such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) are used to diagnose FMD by visualizing the typical beading in affected arteries. Differential diagnoses include atherosclerotic disease, vasculitis, and arterial dissection.\n\n**Management Principles**\n\nManagement involves a comprehensive vascular evaluation. For patients with significant renal involvement, percutaneous transluminal angioplasty may be indicated to manage renovascular hypertension. Stroke management follows standard protocols including antiplatelet therapy and risk factor modification. In pregnant or lactating patients, blood pressure control is critical, and interventions such as angioplasty are considered only if clearly indicated, with careful minimization of radiation exposure.\n\n**Option Analysis**\n\nOption A (Renal Angio) is correct because once FMD is identified in a stroke patient, screening the renal arteries for involvement is essential for complete management. Other options would not address the need for a full vascular workup in FMD.\n\n**Clinical Pearls**\n\n1) FMD is more common in young to middle-aged women and often involves multiple vascular territories. 2) Renal artery involvement in FMD can lead to secondary hypertension, necessitating early detection and appropriate intervention.\n\n**Current Evidence**\n\nRecent guidelines support the use of non-invasive angiographic techniques for diagnosing FMD and emphasize a multidisciplinary approach. Research continues to refine risk stratification and individualized treatment strategies, particularly concerning endovascular versus medical management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 285,
    "question": "MRI with dissection, what to do:",
    "option_a": "Medical Therapy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe key concept is recognizing that an arterial dissection identified on MRI\u2014typically a cervical (carotid or vertebral) artery dissection\u2014is primarily managed medically. Dissections occur when there is a tear in the artery\u2019s intima allowing blood to enter the vessel wall, and this can lead to luminal stenosis, thrombus formation, and embolic stroke. The appropriate initial step is to institute antithrombotic therapy (antiplatelet or anticoagulation), which is encompassed under the term 'Medical Therapy'.\n\n**Pathophysiology**\n\nAn arterial dissection involves an intimal tear that permits blood to dissect into the media layer, creating a false lumen accompanied by an intramural hematoma. This process can cause vessel narrowing or occlusion and may predispose to thrombus formation with subsequent embolization, which is the primary mechanism for ischemic stroke in these patients.\n\n**Clinical Correlation**\n\nPatients with cervical artery dissections may present with unilateral neck pain, headache (often localized), and in carotid dissections, signs such as partial Horner syndrome. Neurologic deficits may occur if the dissection results in compromised cerebral blood flow or embolic stroke. Prompt diagnosis via imaging (such as MRI/MRA) is crucial for initiating treatment.\n\n**Diagnostic Approach**\n\nWhen clinical evaluation suggests an arterial dissection, MRI (along with MRA/CTA) is used to identify features such as an intramural hematoma and double lumen. Differential diagnoses include atherosclerotic vascular disease or vasculitis; however, the imaging characteristics (e.g., crescent-shaped hyperintensity on fat-suppressed sequences) aid in distinguishing a dissection from other vascular pathologies.\n\n**Management Principles**\n\nThe current guidelines (including recommendations from the AHA/ASA and evidence from the CADISS trial) support the use of medical management with antithrombotic therapy as the first-line treatment. This may be achieved with either anticoagulants (such as heparin transitioning to warfarin or direct oral anticoagulants) or antiplatelet agents (such as aspirin). In pregnancy, LMWH is preferred over warfarin due to teratogenic risks; low-dose aspirin is also considered safe. During lactation, both LMWH and low-dose aspirin are generally acceptable. Surgical or endovascular interventions are reserved for patients with progression or complications refractory to medical management.\n\n**Option Analysis**\n\nThe provided answer option, 'Medical Therapy', correctly encompasses the standard initial treatment for a cervical artery dissection. Other potential options (e.g., surgical intervention or conservative observational management without antithrombotic therapy) are less appropriate in the absence of contraindications or complicating factors. Thus, the marked answer A is correct.\n\n**Clinical Pearls**\n\n\u2022 Early recognition is critical in managing cervical artery dissection to prevent stroke. \n\u2022 Both antiplatelet and anticoagulation strategies have demonstrated similar efficacy; selection should be individualized based on patient factors and contraindications. \n\u2022 In pregnancy, consider LMWH and low-dose aspirin as safe options. \n\u2022 Follow-up imaging is important to assess healing and rule out complications such as pseudoaneurysm formation.\n\n**Current Evidence**\n\nRecent evidence from the CADISS trial has shown no significant difference in stroke prevention between anticoagulant and antiplatelet therapies for cervical artery dissections. Updated guidelines advocate for a medical management approach initially, with adjustments based on patient-specific factors including pregnancy and lactation where LMWH and aspirin are favored due to their safety profiles.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 286,
    "question": "73 years old female patient presented with decrease LOC showing hemorrhage with fluid level:",
    "option_a": "Amyloid",
    "option_b": "CVT",
    "option_c": "Anticoagulation use",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case describes an elderly patient (73 years old) with decreased level of consciousness and imaging showing a hemorrhage with a fluid level. A fluid\u2013fluid level within a hemorrhage is a radiologic sign often associated with coagulopathy or the effects of anticoagulation, where the blood fails to clot uniformly, leading to layering of blood components. Although lobar hemorrhages in the elderly can also be due to cerebral amyloid angiopathy, the presence of a fluid level is more characteristic of bleeding in the setting of anticoagulant use.\n\n**Pathophysiology**\n\nIn patients on anticoagulant therapy (e.g., warfarin or direct oral anticoagulants), the normal clotting cascade is impaired. This leads to less effective clot formation and allows blood to remain in a liquid state for longer periods. Consequently, red blood cells may settle out, creating a visible fluid\u2013fluid level on imaging studies. This phenomenon is less typical in conditions like cerebral amyloid angiopathy or hemorrhagic venous infarctions seen in CVT.\n\n**Clinical Correlation**\n\nElderly patients are often on anticoagulant therapy for conditions such as atrial fibrillation, mechanical heart valves, or a history of thromboembolism. In such patients, even minor head trauma or spontaneous bleeding can lead to significant intracranial hemorrhage. Decreased level of consciousness is a common manifestation, and the imaging finding of a fluid level within the hemorrhage further supports a coagulopathy-related bleed.\n\n**Diagnostic Approach**\n\nWhen evaluating an intracranial hemorrhage in an elderly patient, it is essential to review the medication history (especially anticoagulant use), blood coagulation profiles, and correlate clinical symptoms with imaging findings. Differential diagnoses include: 1) Cerebral amyloid angiopathy, which typically causes lobar hemorrhages but without a distinct fluid level; 2) Cerebral venous thrombosis (CVT), which may lead to hemorrhagic infarcts but is less likely in this age group and with this imaging characteristic; 3) Anticoagulation-induced hemorrhage, which is strongly suggested by the presence of a fluid level.\n\n**Management Principles**\n\nManagement of anticoagulation-induced intracranial hemorrhage involves immediate stabilization of the patient, blood pressure control, and reversal of the anticoagulation. This might include the administration of vitamin K and prothrombin complex concentrate for warfarin-related bleed or specific reversal agents (e.g., idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) when indicated. In pregnant or lactating patients (though not applicable in this 73-year-old case), management decisions would consider the safety of reversal agents; current guidelines recommend using agents with established safety profiles in pregnancy when reversal of anticoagulation is needed, with multidisciplinary consultation involving neurology, obstetrics, and hematology.\n\n**Option Analysis**\n\nOption A (Amyloid) is less likely because while cerebral amyloid angiopathy causes lobar hemorrhage, it does not typically produce a fluid\u2013fluid level. Option B (CVT) can lead to hemorrhagic infarcts but is not commonly associated with a fluid level and is more frequent in younger individuals. Option D is absent. Therefore, option C (Anticoagulation use) is the most consistent with the clinical and radiologic findings described.\n\n**Clinical Pearls**\n\n\u2022 A fluid\u2013fluid level in an intracranial hemorrhage should prompt evaluation for coagulopathy or anticoagulation use. \u2022 A thorough medication history is critical in elderly patients presenting with hemorrhage. \u2022 Reversal of anticoagulation is a key step in management to prevent hemorrhage expansion.\n\n**Current Evidence**\n\nRecent guidelines emphasize the importance of early recognition and reversal of anticoagulation in the setting of intracranial hemorrhage to reduce morbidity and mortality. Studies support the use of rapid reversal agents and multidisciplinary approaches for optimal outcomes. Although cerebral amyloid angiopathy is a common cause of lobar hemorrhages in the elderly, the imaging finding of a fluid level is most consistent with anticoagulant-associated bleeding, which is supported by current clinical and radiographic evidence.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "id": 287,
    "question": "What is the artey?",
    "option_a": "mca",
    "option_b": "pca",
    "option_c": "ant choroidal artery",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question appears to assess knowledge of cerebral vascular anatomy. The options reference major cerebral arteries: the middle cerebral artery (MCA), posterior cerebral artery (PCA), and the anterior choroidal artery. The anterior choroidal artery is a smaller, but clinically important vessel that typically arises from the internal carotid artery. It supplies critical regions such as portions of the internal capsule, optic tract, and parts of the choroid plexus of the lateral ventricle.\n\n**Pathophysiology**\n\nOcclusion or infarction in the territory of the anterior choroidal artery can produce the classic anterior choroidal syndrome, which may result in contralateral hemiparesis, hemisensory deficits, and homonymous hemianopia. Its small size and the fact that it supplies deep brain structures underscore the clinical relevance when vascular compromise occurs.\n\n**Clinical Correlation**\n\nClinically, patients with an infarct in the anterior choroidal artery territory may present with a combination of motor, sensory, and visual deficits. Recognizing the distribution of neurological deficits can help distinguish strokes in this territory from those involving the MCA (which usually involves lateral cortical areas) or PCA (which often present with primary visual field deficits without the same degree of motor involvement).\n\n**Diagnostic Approach**\n\nIn practice, neuroimaging such as CT angiography or MR angiography is used to delineate the vascular territories and identify the culprit vessel. The differential diagnosis involves distinguishing between larger vessel strokes (MCA or PCA territory) and smaller deep infarcts. In a stroke setting, clinical findings supported by imaging can lead to targeted management.\n\n**Management Principles**\n\nManagement of an infarct in the anterior choroidal artery territory follows general ischemic stroke guidelines, including rapid revascularization therapy (e.g., IV thrombolysis if within therapeutic window) and secondary prevention (antiplatelet therapy, blood pressure control, and management of risk factors). In pregnancy, thrombolytic therapy (such as IV alteplase) can be considered after a careful risk-benefit analysis, and imaging modalities are selected to minimize fetal exposure. For lactating patients, standard stroke treatments are generally continued with counseling regarding medication safety during lactation.\n\n**Option Analysis**\n\nOption A (MCA) and Option B (PCA) both represent major cerebral arteries with distinct territorial supplies. The middle cerebral artery supplies large portions of the lateral cerebral cortex, whereas the posterior cerebral artery primarily supplies the occipital lobes. The anterior choroidal artery, Option C, is a small but critical branch commonly arising from the internal carotid artery, and it has a well-defined territory that, when infarcted, produces a distinct clinical picture. The marked answer, Option C, is the appropriate and most specific answer given the likely intent of the question.\n\n**Clinical Pearls**\n\n\u2022 The anterior choroidal artery supplies key deep brain structures including portions of the internal capsule and the optic tract.  \u2022 Infarcts in its territory may cause a combination of motor, sensory, and visual deficits (anterior choroidal artery syndrome).  \u2022 Timely identification of the involved artery via imaging is critical for rapid intervention.  \u2022 In pregnant or lactating patients, modifications in imaging technique and therapy (e.g., thrombolytics) need to be considered according to current guidelines.\n\n**Current Evidence**\n\nRecent stroke management guidelines emphasize rapid identification of the vascular occlusion and tailored reperfusion strategies. Advances in imaging have allowed more precise localization of infarcts even in small arterial territories such as the anterior choroidal artery. Moreover, evidence supports that standard stroke treatments can be safely and effectively modified for use in pregnant and lactating patients, with careful monitoring and risk assessment.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 288,
    "question": "What yoi will do?",
    "option_a": "Shunt",
    "option_b": "anticoagulant",
    "option_c": "give",
    "option_d": "give LMWH",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn neurology and neurosurgery, a shunt procedure is employed to divert cerebrospinal fluid (CSF) and thereby relieve the signs and symptoms of hydrocephalus. Hydrocephalus may be obstructive (non-communicating) or communicating, and when medical management fails or is not indicated, surgical CSF diversion via shunting (typically a ventriculoperitoneal shunt) is the definitive treatment.\n\n**Pathophysiology**\n\nHydrocephalus results from an imbalance between CSF production and absorption or from an obstruction of CSF flow. This leads to an accumulation of CSF within the ventricular system, causing increased intracranial pressure. Over time, this pressure can compress brain tissue and lead to neurological deficits. The shunt bypasses the obstructed flow, allowing CSF to be diverted from the ventricles to another body cavity (usually the peritoneal cavity) where it can be absorbed.\n\n**Clinical Correlation**\n\nPatients with hydrocephalus may present with symptoms such as headache, nausea, vomiting, altered mental status, gait disturbances, and in some cases cognitive impairment. In conditions like normal pressure hydrocephalus (NPH), the classic clinical triad includes gait apraxia, dementia, and urinary incontinence. The decision to place a shunt is based on clinical findings as well as radiologic evidence of ventriculomegaly.\n\n**Diagnostic Approach**\n\nDiagnosis requires neuroimaging, usually with CT or MRI. These studies help to confirm ventriculomegaly and to differentiate between communicating and non\u2010communicating causes of hydrocephalus. A lumbar puncture (after imaging rules out mass lesions) may also be used diagnostically especially in NPH where a large volume tap test can predict shunting success.\n\n**Management Principles**\n\nThe standard management of symptomatic hydrocephalus is CSF diversion by shunt placement. Current guidelines suggest that shunting is indicated in patients with confirmed hydrocephalus who have corresponding clinical symptoms. In pregnant patients, the decision to intervene surgically is based on symptom severity and risks. While the procedure itself carries risks inherent to surgery and anesthesia, multidisciplinary planning can minimize fetal risk. For lactating patients, shunt surgery is also considered safe, although supportive care and coordination with obstetrics is advisable.\n\n**Option Analysis**\n\nOption A (Shunt) is the only answer that corresponds to a definitive treatment in a scenario that implies a CSF diversion need. Options B (anticoagulant) and D (give LMWH) are relevant for conditions like cerebral venous sinus thrombosis and are not indicated in hydrocephalus unless there is an overlapping thromboembolic event. Option C ('give') is incomplete and non-specific. Given the context and the management strategy for hydrocephalus, the shunt option is the most appropriate.\n\n**Clinical Pearls**\n\n\u2022 Always correlate clinical symptoms with imaging findings to confirm the diagnosis of hydrocephalus before proceeding with shunt placement. \u2022 In cases of ambiguous neurological presentations, distinguishing between vascular (e.g., CVT requiring anticoagulation) and CSF flow disorders (requiring shunting) is key. \u2022 In special populations like pregnant or lactating women, multidisciplinary care ensures that both maternal and fetal/neonatal risks are minimized.\n\n**Current Evidence**\n\nRecent guidelines and studies continue to endorse CSF shunting (particularly ventriculoperitoneal shunting) as the gold standard for managing symptomatic hydrocephalus. Surgical techniques and postoperative care protocols have improved, reducing complications. In clinical practice, careful selection and preoperative testing (sometimes including a lumbar drain trial) help improve outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 289,
    "question": "What is the mechanism?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "T",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question is centered on identifying the underlying mechanism responsible for a hemorrhagic event. It requires distinguishing between structural causes (such as hypertension-induced vessel changes or aneurysmal rupture) and systemic causes (like coagulopathy) that affect the clotting cascade. In this scenario, the key is recognizing that an impaired coagulation mechanism directly predisposes to bleeding.\n\n**Pathophysiology**\n\nCoagulopathies impair the normal clotting cascade\u2014whether due to anticoagulant medication, liver dysfunction, or congenital disorders\u2014resulting in an inability to form stable fibrin clots. Unlike hemorrhages secondary to chronic hypertension (which result from long-term vascular remodeling and are typically seen in deep brain structures) or aneurysms (which usually cause sudden subarachnoid bleeding), coagulopathy-associated hemorrhages stem from a systemic deficiency in clot formation leading to spontaneous bleeding even without pre-existing vascular lesions.\n\n**Clinical Correlation**\n\nPatients with coagulopathy\u2010induced hemorrhages may present with intracerebral bleeding that appears in atypical locations compared to the classic deep brain regions seen in hypertensive hemorrhage. Laboratory tests (such as PT, INR, and PTT) help confirm the diagnosis. Clinically, the lack of a history of severe hypertension or aneurysmal symptoms combined with abnormal coagulation profiles should guide clinicians toward this diagnosis.\n\n**Diagnostic Approach**\n\nThe diagnostic workup includes neuroimaging (CT/MRI) to determine the location and pattern of hemorrhage, along with coagulation studies to assess clotting function. Differential diagnoses include: 1) Hypertensive hemorrhage (typically in the basal ganglia, thalamus, or cerebellum) characterized by a history of chronic hypertension; 2) Aneurysmal rupture, which classically causes subarachnoid hemorrhage; and 3) Other vascular malformations that usually have distinct imaging patterns.\n\n**Management Principles**\n\nManagement focuses on rapid stabilization and reversal of the coagulopathic state. First-line interventions include administration of vitamin K, fresh frozen plasma, or prothrombin complex concentrates based on the underlying cause. In cases where anticoagulant medications are involved, specific reversal agents (for example, idarucizumab for dabigatran) may be required. In pregnant or lactating patients, the decision to reverse a coagulopathy must balance maternal risks with fetal considerations; many reversal agents have been studied in these populations, and a multidisciplinary approach (involving obstetrics and hematology) is advised.\n\n**Option Analysis**\n\n\u2022 Option 1 (Hypertension): Incorrect because while chronic HTN can cause hemorrhage, it typically does so through long-term vascular changes rather than through an acute impairment of coagulation. \u2022 Option 2 (Coagulopathy): Correct since a systemic clotting defect disrupts normal hemostasis and predisposes to bleeding. \u2022 Option 3 (Aneurysm): Incorrect as aneurysms lead to hemorrhage via focal arterial dilation and rupture, usually resulting in subarachnoid hemorrhage.\n\n**Clinical Pearls**\n\n1. In the absence of typical risk factors like chronic hypertension, always consider a coagulopathy when evaluating spontaneous intracranial hemorrhage. 2. Rapid identification and reversal of a coagulation defect can prevent further bleeding and improve outcomes.\n\n**Current Evidence**\n\nRecent literature emphasizes the importance of differentiating hemorrhage etiologies because treatment differs markedly. Advances in specific reversal agents have improved outcomes in coagulopathy\u2010induced hemorrhages. Current guidelines stress the prompt correction of coagulation abnormalities, particularly in patients receiving anticoagulants.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 290,
    "question": "82 years old male pt came within 3 hrs and have no contraindication for tpa and ct attached with early signe of stroke but infarction not established what you will give",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "tpa",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question tests the acute management of ischemic stroke within the therapeutic time window. The central concept is that timely administration of a thrombolytic agent, such as tissue plasminogen activator (tPA), significantly improves neurological outcomes by dissolving the clot obstructing cerebral blood flow.\n\n**Pathophysiology**\n\nAcute ischemic stroke is caused by an arterial occlusion that leads to cerebral ischemia. tPA acts by converting plasminogen to plasmin, which then degrades fibrin, effectively lysing the clot and restoring blood flow to the affected brain region. This reperfusion of the penumbra limits infarct size.\n\n**Clinical Correlation**\n\nIn the clinical scenario described, the 82-year-old male presents within a crucial 3-hour window, where early CT imaging reveals subtle signs of ischemia without established infarction, making him an ideal candidate for tPA. Despite advanced age, the eligibility criteria for tPA are met, reflecting current practices where age alone is not a contraindication.\n\n**Diagnostic Approach**\n\nDiagnosis is confirmed with a non-contrast CT scan to rule out hemorrhage and ascertain the absence of significant infarction. Differential considerations include transient ischemic attack (TIA) and hemorrhagic stroke, but rapid imaging and clinical examination help exclude these possibilities.\n\n**Management Principles**\n\nFirst-line treatment for eligible patients with acute ischemic stroke is IV tPA administered within 3 to 4.5 hours of symptom onset. If patients present outside this window or have contraindications, alternative interventions such as mechanical thrombectomy may be considered. For pregnant patients facing stroke, tPA can be administered after careful risk-benefit analysis and consultation with obstetric specialists, as improved maternal outcomes often translate into better fetal outcomes. In lactating women, tPA administration is generally considered safe, but appropriate counseling is recommended.\n\n**Option Analysis**\n\n\u2022 Option A (Aspirin) and Option B (Plavix): These antiplatelet agents are used for long-term secondary prevention, not for acute thrombolysis. \u2022 Option C (tPA): Correct, as it addresses the need for prompt thrombolysis in acute ischemic stroke. \u2022 Option D: Not provided and unnecessary in this context.\n\n**Clinical Pearls**\n\n1. The mantra 'time is brain' underlines the importance of rapid thrombolytic therapy in acute stroke management. 2. Advanced age should not preclude the use of tPA if other eligibility criteria are satisfied.\n\n**Current Evidence**\n\nRecent studies and stroke guidelines (e.g., those from the American Heart Association) reinforce the use of IV tPA in eligible patients within the tight treatment window. Continuous updates in stroke care protocols stress rapid imaging and swift decision-making, and recent research supports the safety and effectiveness of tPA even in older populations.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]